Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.82 |
| ▸ | PGR | P06401 | 3/20 | 0.82 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | AR | P10275 | 2/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.74 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | SHBG | P04278 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018308 | 0.93 | HIF1A (0.93) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL10944869 | 0.92 | HIF1A (0.84) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL11234120 | 0.92 | HIF1A (0.84) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL10940291 | 0.92 | HIF1A (0.84) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL180225 | 0.92 | HIF1A (0.84) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL13669677 | 0.92 | HIF1A (0.84) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL4450339 | 0.92 | HIF1A (0.84) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL6425290 | 0.91 | HIF1A (0.82) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL2679655 | 0.91 | HIF1A (0.88) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL10575587 | 0.91 | HIF1A (0.88) | HIF1APGRSERPINA6LMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8729010-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729010-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8623833-B2 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623833-B2 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | CELLGATE, INC., A DELAWARE CORPORATION | 2013-04-18 | — | — | US | disclosed |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | CELLGATE, INC., A DELAWARE CORPORATION | 2013-04-18 | — | — | US | disclosed |
| US-8278264-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278264-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100081618-A1 | Transporters Comprising Spaced Arginine Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-7585834-B2 | Transporters comprising spaced arginine moieties | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585834-B2 | Transporters comprising spaced arginine moieties | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1401473-B1 | TRANSPORTERS COMPRISING SPACED ARGININE MOIETIES | CELLGATE INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070173436-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | CELLGATE, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173436-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | CELLGATE, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-7229961-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229961-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081618-A1 | Transporters Comprising Spaced Arginine Moieties | SLC43A1, SLC1A5, SLC7A5 | HIF1A 2713/4885PGR 2178/4885SERPINA6 3267/4885 |
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | SLC7A1, ADM2, ARG1 | HIF1A 1222/4885PGR 791/4885SERPINA6 1117/4885 |
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | ADM2, SLC7A1, ARG1 | HIF1A 1468/4885PGR 674/4885SERPINA6 1236/4885 |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | SLC7A1, ADM2, ARG1 | HIF1A 1222/4885PGR 791/4885SERPINA6 1117/4885 |
| US-20070173436-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | SLC7A1, ADM2, ARG1 | HIF1A 1219/4885PGR 733/4885SERPINA6 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.